Literature DB >> 18796265

Chemotherapy-induced peripheral neuropathy.

Bushra Malik1, Mark Stillman.   

Abstract

Recent advances in the development and administration of chemotherapy for malignant diseases have led to prolonged survival of patients and the promise of a return to normal lives. This progress comes with a price, however, and the nervous system is frequently the target of therapy-induced toxicity. Unlike more immediate toxicities that affect the gastrointestinal tract and bone marrow, chemotherapy-induced neurotoxicity is frequently delayed in onset and may progress over time. In the peripheral nervous system, the major brunt of the toxic attack is directed against the peripheral nerve, targeting the neuronal cell body, the axonal transport system, the myelin sheath, and glial support structures, resulting in chemotherapy-induced peripheral neuropathy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18796265     DOI: 10.1007/s11916-008-0030-5

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  47 in total

1.  Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies.

Authors:  D N Herrmann; J W Griffin; P Hauer; D R Cornblath; J C McArthur
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

Review 2.  Grading of chemotherapy-induced peripheral neuropathy.

Authors:  T J Postma; J J Heimans
Journal:  Ann Oncol       Date:  2000-05       Impact factor: 32.976

3.  Chemotherapy-induced peripheral neuropathy: an increasing concern for oncologists.

Authors:  Maurie Markman
Journal:  Curr Oncol Rep       Date:  2005-05       Impact factor: 5.075

Review 4.  Clinical approach to patients with neuropathic pain.

Authors:  Mark Stillman
Journal:  Cleve Clin J Med       Date:  2006-08       Impact factor: 2.321

5.  Glutamine as a neuroprotective agent in high-dose paclitaxel-induced peripheral neuropathy: a clinical and electrophysiologic study.

Authors:  M D Stubblefield; L T Vahdat; C M Balmaceda; A B Troxel; C S Hesdorffer; C L Gooch
Journal:  Clin Oncol (R Coll Radiol)       Date:  2005-06       Impact factor: 4.126

Review 6.  Management of chemotherapy-induced peripheral neuropathy.

Authors:  Mark Stillman; Juan P Cata
Journal:  Curr Pain Headache Rep       Date:  2006-08

Review 7.  Medication and toxin-induced peripheral neuropathy.

Authors:  Robert W Pratt; Louis H Weimer
Journal:  Semin Neurol       Date:  2005-06       Impact factor: 3.420

8.  Neuronal involvement in cisplatin neuropathy: prospective clinical and neurophysiological studies.

Authors:  A Krarup-Hansen; S Helweg-Larsen; H Schmalbruch; M Rørth; C Krarup
Journal:  Brain       Date:  2007-02-14       Impact factor: 13.501

9.  Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine.

Authors:  Giulia Bianchi; Giordano Vitali; Augusto Caraceni; Sabrina Ravaglia; Giuseppe Capri; Sante Cundari; Claudio Zanna; Luca Gianni
Journal:  Eur J Cancer       Date:  2005-08       Impact factor: 9.162

10.  Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy.

Authors:  B G McCarthy; S T Hsieh; A Stocks; P Hauer; C Macko; D R Cornblath; J W Griffin; J C McArthur
Journal:  Neurology       Date:  1995-10       Impact factor: 9.910

View more
  2 in total

1.  Impact of kinesin Eg5 inhibition by 3,4-dihydropyrimidin-2(1H)-one derivatives on various breast cancer cell features.

Authors:  Bruna C Guido; Luciana M Ramos; Diego O Nolasco; Catharine C Nobrega; Bárbara Y G Andrade; Aline Pic-Taylor; Brenno A D Neto; José R Corrêa
Journal:  BMC Cancer       Date:  2015-04-14       Impact factor: 4.430

2.  Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients.

Authors:  Makoto Nagashima; Mitsuru Ooshiro; Ayako Moriyama; Yui Sugishita; Kengo Kadoya; Ayami Sato; Tomoaki Kitahara; Ryuichi Takagi; Tasuku Urita; Yutaka Yoshida; Hiroshi Tanaka; Takashi Oshiro; Shinichi Okazumi; Ryoji Katoh
Journal:  Support Care Cancer       Date:  2014-01-24       Impact factor: 3.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.